Our approach
We're on a mission to get new drug treatments into the hands of rare disease patients. Quickly. Safely. Cost-effectively.
Rethinking rare disease
-
We help healthcare systems identify their undiagnosed rare disease patients by analyzing electronic health records.
-
We accelerate drug development by strategically acquiring late-stage assets with the potential for approval in rare disease indications where there is no current drug treatment.
Finding needles in a haystack with MagentID
®
The road to diagnosis is often called an “odyssey” – with an average time to diagnosis of 6 years, and multiple misdiagnoses along the way.
We help healthcare providers to find their undiagnosed patients.
MagnetID is a sophisticated AI platform developed over a decade by our partner, to identify the patients who may have an undiagosed rare disease. Like switching on a magnet to draw the needles out of a haystack.
Whether you are searching for a single rare disease or multiple among your patient population, we can help.
Using this AI-powered software, our MagnetID services interrogates elecrtonic patient records within healthcare systems, matching patient symptoms with a database of phenotypes from 7,000 rare diseases. This could help accelerate patient diagnoses, reduce healthcare costs, and help gain a better understanding of rare disease populations.
In rare diseases, we can only solve problems that we know exist.
®
®
Bringing stalled drugs to market
Our core business focuses on bringing rare disease drugs to market. Quickly. Safely. And cost-effectively.
With 95% of rare diseases having no approved treatment, it is clear that existing approaches aren't enough. Mainstream drug development costs are high and promising drug candidates can be left on the shelf; rare diseases regulatory incentives can provide new opportunities for them.
At the current rate of development, it is estimated that it will take over a century before every rare disease has an approved drug treatment.
So, we are using our expertise and deep understanding of rare diseases to take a different approach.
Using our in-house asset evaluator, we identify, acquire, develop, and commercialize drug candidates that have already generated safety and efficacy data that show potential for regulatory approval in a rare disease indication where there is no current approved drug treatment.
We reinvigorate these assets by leveraging our knowledge of rare disease regulatory pathways, establishing relevant clinical study endpoints and engaging with patients from the start. This is how we hope to bring new drug therapies to market in half the time compared to current industry standards, and at a lower cost.
Our growing drug development pipeline focuses on indications where there is no existing, approved drug treatment.